However, not all cases respond equally to ICI treatment, and different predictors of response have been suggested (e.g., PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, tumor-associated macrophages) [8, 9]. The gene discussed is CD274; the disease is neoplasm.